Veracyte [VCYT] vs Danaher [DHR] Detailed Stock Comparison
Veracyte
NASDAQ
Loading...
Danaher
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Veracyte wins in 6 metrics, Danaher wins in 13 metrics, with 0 ties. Danaher appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Veracyte | Danaher | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 105.88 | 45.65 | Danaher |
| Price-to-Book Ratio | 2.32 | 2.94 | Veracyte |
| Debt-to-Equity Ratio | 4.15 | 35.45 | Veracyte |
| PEG Ratio | -0.93 | -1.22 | Danaher |
| EV/EBITDA | 40.17 | 22.54 | Danaher |
| Profit Margin (TTM) | 5.50% | 14.21% | Danaher |
| Operating Margin (TTM) | 11.00% | 20.12% | Danaher |
| EBITDA Margin (TTM) | 11.00% | 20.12% | Danaher |
| Return on Equity | 2.24% | 6.68% | Danaher |
| Return on Assets (TTM) | 1.98% | 4.01% | Danaher |
| Free Cash Flow (TTM) | $63.81M | $5.30B | Danaher |
| 1-Year Return | 5.94% | -21.68% | Veracyte |
| Price-to-Sales Ratio (TTM) | 5.91 | 6.41 | Veracyte |
| Enterprise Value | $2.56B | $169.55B | Danaher |
| EV/Revenue Ratio | 5.35 | 7.06 | Veracyte |
| Gross Profit Margin (TTM) | 68.97% | 59.35% | Veracyte |
| Revenue per Share (TTM) | $6 | $33 | Danaher |
| Earnings per Share (Diluted) | $0.34 | $4.71 | Danaher |
| Beta (Stock Volatility) | 2.12 | 0.80 | Danaher |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Veracyte vs Danaher Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Veracyte | 0.11% | 7.23% | 11.03% | 36.83% | 22.05% | -10.88% |
| Danaher | -1.53% | 13.79% | 6.59% | 6.05% | 17.21% | -7.88% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Veracyte | 5.94% | 130.88% | -15.83% | 452.76% | 193.01% | 193.01% |
| Danaher | -21.68% | -5.87% | 4.99% | 254.15% | 651.28% | 1,113.24% |
News Based Sentiment: Veracyte vs Danaher
Veracyte
News based Sentiment: MIXED
October was a month of contrasts for Veracyte, marked by significant insider selling alongside positive stock performance and optimistic analyst ratings. While the insider activity warrants attention, the overall narrative suggests a company with growth potential facing both opportunities and risks.
Danaher
News based Sentiment: MIXED
Danaher delivered a mixed month, with strong Q2 results and positive developments in AI and potential tariff benefits offset by challenges in the Life Sciences segment and differing analyst opinions. The company's overall outlook remains positive, but investors should monitor key areas for potential risks and opportunities.
Performance & Financial Health Analysis: Veracyte vs Danaher
| Metric | VCYT | DHR |
|---|---|---|
| Market Information | ||
| Market Cap | $2.83B | $153.94B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 894,093 | 5,958,360 |
| 90 Day Avg. Volume | 967,581 | 4,345,910 |
| Last Close | $36.04 | $211.71 |
| 52 Week Range | $22.61 - $47.32 | $171.00 - $279.41 |
| % from 52W High | -23.83% | -24.23% |
| All-Time High | $86.03 (Feb 08, 2021) | $296.06 (Sep 06, 2021) |
| % from All-Time High | -58.11% | -28.49% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.14% | 0.03% |
| Quarterly Earnings Growth | 0.14% | -0.39% |
| Financial Health | ||
| Profit Margin (TTM) | 0.06% | 0.14% |
| Operating Margin (TTM) | 0.11% | 0.20% |
| Return on Equity (TTM) | 0.02% | 0.07% |
| Debt to Equity (MRQ) | 4.15 | 35.45 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $15.54 | $73.10 |
| Cash per Share (MRQ) | $4.08 | $4.13 |
| Operating Cash Flow (TTM) | $93.45M | $6.17B |
| Levered Free Cash Flow (TTM) | $75.40M | $3.88B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Veracyte vs Danaher
| Metric | VCYT | DHR |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 105.88 | 45.65 |
| Forward P/E | 90.00 | 25.66 |
| PEG Ratio | -0.93 | -1.22 |
| Price to Sales (TTM) | 5.91 | 6.41 |
| Price to Book (MRQ) | 2.32 | 2.94 |
| Market Capitalization | ||
| Market Capitalization | $2.83B | $153.94B |
| Enterprise Value | $2.56B | $169.55B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.35 | 7.06 |
| Enterprise to EBITDA | 40.17 | 22.54 |
| Risk & Other Metrics | ||
| Beta | 2.12 | 0.80 |
| Book Value per Share (MRQ) | $15.54 | $73.10 |
Financial Statements Comparison: Veracyte vs Danaher
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | VCYT | DHR |
|---|---|---|
| Revenue/Sales | $114.47M | $5.74B |
| Cost of Goods Sold | $34.97M | $2.23B |
| Gross Profit | $79.51M | $3.51B |
| Research & Development | $17.72M | $379.00M |
| Operating Income (EBIT) | $1.16M | $1.27B |
| EBITDA | $3.03M | $1.87B |
| Pre-Tax Income | $7.43M | $1.13B |
| Income Tax | $381,000 | $175.00M |
| Net Income (Profit) | $7.05M | $954.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | VCYT | DHR |
|---|---|---|
| Cash & Equivalents | $186.12M | $1.99B |
| Total Current Assets | $383.15M | $9.53B |
| Total Current Liabilities | $75.13M | $6.65B |
| Long-Term Debt | $43.09M | $15.98B |
| Total Shareholders Equity | $1.19B | $50.86B |
| Retained Earnings | $-436.94M | $44.91B |
| Property, Plant & Equipment | $70.15M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | VCYT | DHR |
|---|---|---|
| Operating Cash Flow | $18.76M | $1.47B |
| Capital Expenditures | $-1.82M | $-239.00M |
| Free Cash Flow | $3.54M | $1.05B |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | $-1.08B |
Short Interest & Institutional Ownership Analysis
| Metric | VCYT | DHR |
|---|---|---|
| Shares Short | 9.13M | 9.53M |
| Short Ratio | 9.44 | 2.85 |
| Short % of Float | 0.13% | 0.01% |
| Average Daily Volume (10 Day) | 894,093 | 5,958,360 |
| Average Daily Volume (90 Day) | 967,581 | 4,345,910 |
| Shares Outstanding | 77.77M | 719.10M |
| Float Shares | 78.21M | 637.13M |
| % Held by Insiders | 0.01% | 0.11% |
| % Held by Institutions | 1.09% | 0.83% |
Dividend Analysis & Yield Comparison: Veracyte vs Danaher
| Metric | VCYT | DHR |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |